title: DPP-4 Inhibitor Treatment in Chinese Type 2 Diabetes Patients: A Meta-Analysis.
abstract: The aim of this meta-analysis was to assess the comprehensive clinical efficacy of dipeptidyl peptidase-IV (DPP-4) inhibitors in Chinese type 2 diabetes patients and to evaluate whether there is a different response to treatment with different kinds of DPP-4 inhibitors in those patients.
  
  
  
  Databases were systematically searched, and qualifying clinical studies of Chinese type 2 diabetes patients were included.
  
  
  
  A total of 30 studies were included. Treatment with saxagliptin resulted in a significantly greater change from baseline in HbA1clevels (weighted mean difference [WMD], -1.28%; 95% CI, -1.37% to -1.19%); treatment with sitagliptin led to a significantly greater change from baseline (WMD, -1.17%; 95% CI, -1.46% to -0.89%); treatment with vildagliptin was associated with a significantly greater change in HbA1clevels (WMD, -0.77%; 95% CI, -0.88% to -0.65%); treatment with linagliptin led to a significantly greater change (WMD, -0.84%; 95% CI, -0.92% to -0.75%); and treatment with alogliptin also led to a significantly greater change (WMD, -0.91%; 95% CI, -1.48% to -0.33%). In terms of body weight, treatment with saxagliptin was associated with no significant decreases in Chinese type 2 diabetes mellitus (T2DM) patients (WMD, -0.17 kg, 95% CI, -4.26 to 3.92 kg). Treatment with sitagliptin and linagliptin was also associated with no significant changes in body weight (WMD, 0.16 and 0.11 kg, respectively, P > 0.05).
  
  
  
  In Chinese type 2 diabetes patients, the efficacy of glucose control in all five kinds of DPP-4 inhibitor treatments was well confirmed, and no significant change in body weight was found.
authors.affiliation: Department of Endocrinology and Metabolism, Peking University People's Hospital , Beijing, China .
authors.forename: Xiaoling
authors.initials: X
authors.lastname: Cai
authors.affiliation: Department of Endocrinology and Metabolism, Peking University People's Hospital , Beijing, China .
authors.forename: Xueying
authors.initials: X
authors.lastname: Gao
authors.affiliation: Department of Endocrinology and Metabolism, Peking University People's Hospital , Beijing, China .
authors.forename: Wenjia
authors.initials: W
authors.lastname: Yang
authors.affiliation: Department of Endocrinology and Metabolism, Peking University People's Hospital , Beijing, China .
authors.forename: Yifei
authors.initials: Y
authors.lastname: Chen
authors.affiliation: Department of Endocrinology and Metabolism, Peking University People's Hospital , Beijing, China .
authors.forename: Lingli
authors.initials: L
authors.lastname: Zhou
authors.affiliation: Department of Endocrinology and Metabolism, Peking University People's Hospital , Beijing, China .
authors.forename: Simin
authors.initials: S
authors.lastname: Zhang
authors.affiliation: Department of Endocrinology and Metabolism, Peking University People's Hospital , Beijing, China .
authors.forename: Xueyao
authors.initials: X
authors.lastname: Han
authors.affiliation: Department of Endocrinology and Metabolism, Peking University People's Hospital , Beijing, China .
authors.forename: Linong
authors.initials: L
authors.lastname: Ji
mesh_terms: D044466:Asian People; D002681:China; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000627:therapeutic use*; D006801:Humans; D016896:Treatment Outcome
chemical_list: D054873:Dipeptidyl-Peptidase IV Inhibitors
keywords: Chinese; Dipeptidyl peptidase-4 inhibitor; Meta-analysis; Type 2 diabetes mellitus